司库奇尤单抗治疗银屑病在我国的真实世界研究进展

Progresses in Real-World Research of Secukinumab for the Treatment of Psoriasis in China

本文全面回顾了2018年司库奇尤单抗在海南博鳌乐城国际医疗旅游先行区开展首个治疗银屑病的真实世界研究以来,特别是2019年司库奇尤单抗在我国获批上市至今,治疗的50万我国银屑病患者的基本情况。共计30多个团队开展了司库奇尤单抗真实世界研究,为治疗我国银屑病患者的初步疗效、维持疗效和不良反应等提供了客观证据。研究结果表明,司库奇尤单抗作为靶向IL-17A的生物制剂,在改善银屑病面积和严重程度指数、皮肤病生活质量指数方面效果显著,且不良反应可控。与传统疗法及其他生物制剂相比,显示出更快的起效速度、更稳定的长期疗效以及更低的复发风险。

This article comprehensively reviews the progress of treating 500,000 psoriasis patients in China since the initiation of the first real-world study on secukinumab for psoriasis in the Hainan Boao Lecheng International Medical Tourism Pilot Zone in 2018,particularly following its approval and market release in China in 2019.Over 30 research teams have conducted real-world studies on secukinumab,providing objective evidence regarding its initial efficacy,sustained efficacy,and adverse reactions in China’s psoriasis patients.The results indicate that secukinumab,as an IL-17A-targeting biologic,significantly improves the psoriasis area and severity index and dermatology life quality index,with manageable adverse reactions.Compared with traditional therapies and other biologics,secukinumab exhibits a faster onset,more stable long-term efficacy,and a lower risk of relapse.